Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 13 | 2024 | 218 | 3.580 |
Why?
|
| Macrophages | 8 | 2022 | 529 | 2.330 |
Why?
|
| Reactive Oxygen Species | 5 | 2024 | 532 | 2.090 |
Why?
|
| Cytokines | 7 | 2026 | 678 | 2.030 |
Why?
|
| Prostatic Neoplasms | 6 | 2026 | 1092 | 1.990 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 56 | 1.660 |
Why?
|
| Carcinoma in Situ | 4 | 2017 | 16 | 1.550 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2024 | 67 | 1.500 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2022 | 13 | 1.400 |
Why?
|
| Protein Kinase C | 4 | 2016 | 124 | 1.380 |
Why?
|
| Metaplasia | 6 | 2024 | 39 | 1.180 |
Why?
|
| Pancreatic Ducts | 5 | 2017 | 9 | 1.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 27 | 0.960 |
Why?
|
| Chemokine CCL5 | 1 | 2026 | 41 | 0.960 |
Why?
|
| Interleukin-10 | 1 | 2026 | 87 | 0.930 |
Why?
|
| Cell Proliferation | 6 | 2020 | 1455 | 0.910 |
Why?
|
| Interleukin-6 | 1 | 2026 | 165 | 0.900 |
Why?
|
| B-Lymphocytes | 1 | 2026 | 189 | 0.890 |
Why?
|
| Oxidative Stress | 2 | 2024 | 1003 | 0.870 |
Why?
|
| Disease Progression | 4 | 2017 | 667 | 0.850 |
Why?
|
| Precancerous Conditions | 4 | 2019 | 83 | 0.770 |
Why?
|
| Cell Movement | 3 | 2026 | 655 | 0.760 |
Why?
|
| Pancreas | 4 | 2024 | 45 | 0.750 |
Why?
|
| Signal Transduction | 9 | 2020 | 2157 | 0.730 |
Why?
|
| Prostate | 2 | 2022 | 155 | 0.680 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 299 | 0.640 |
Why?
|
| Inflammation | 3 | 2024 | 758 | 0.600 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2020 | 59 | 0.600 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 196 | 0.570 |
Why?
|
| Prostatic Hyperplasia | 1 | 2018 | 32 | 0.550 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2018 | 108 | 0.540 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2018 | 105 | 0.540 |
Why?
|
| Genes, ras | 2 | 2014 | 24 | 0.530 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 99 | 0.530 |
Why?
|
| Animals | 19 | 2024 | 16992 | 0.530 |
Why?
|
| Interleukin-13 | 1 | 2017 | 20 | 0.520 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 228 | 0.500 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 140 | 0.490 |
Why?
|
| Mice | 11 | 2024 | 6644 | 0.480 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 934 | 0.470 |
Why?
|
| Neoplasms | 2 | 2020 | 1377 | 0.440 |
Why?
|
| Humans | 21 | 2026 | 43102 | 0.420 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 49 | 0.400 |
Why?
|
| Pancreas, Exocrine | 3 | 2017 | 4 | 0.380 |
Why?
|
| Cells, Cultured | 5 | 2020 | 1621 | 0.370 |
Why?
|
| Mitochondria | 1 | 2016 | 523 | 0.360 |
Why?
|
| NF-kappa B | 1 | 2013 | 358 | 0.330 |
Why?
|
| Mutation | 2 | 2015 | 1177 | 0.330 |
Why?
|
| Cell Line, Tumor | 6 | 2026 | 2676 | 0.320 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 21 | 0.320 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 84 | 0.310 |
Why?
|
| Male | 9 | 2026 | 23409 | 0.290 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 665 | 0.290 |
Why?
|
| Cell Line | 4 | 2020 | 1410 | 0.280 |
Why?
|
| Parkinson Disease | 1 | 2009 | 210 | 0.260 |
Why?
|
| Cell Transdifferentiation | 2 | 2017 | 8 | 0.250 |
Why?
|
| Pancreatitis | 2 | 2017 | 21 | 0.240 |
Why?
|
| Coculture Techniques | 1 | 2026 | 109 | 0.240 |
Why?
|
| NF-kappa B p52 Subunit | 2 | 2016 | 4 | 0.220 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2024 | 16 | 0.210 |
Why?
|
| Chemokines, CC | 1 | 2024 | 55 | 0.210 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2016 | 186 | 0.190 |
Why?
|
| Up-Regulation | 2 | 2016 | 536 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2017 | 165 | 0.180 |
Why?
|
| Osteopontin | 1 | 2022 | 46 | 0.180 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 458 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 127 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 95 | 0.150 |
Why?
|
| Thalidomide | 1 | 2019 | 6 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 968 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2019 | 51 | 0.140 |
Why?
|
| Prostatitis | 1 | 2018 | 1 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2024 | 719 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 237 | 0.130 |
Why?
|
| Neutralization Tests | 1 | 2017 | 57 | 0.130 |
Why?
|
| Cell Polarity | 1 | 2017 | 57 | 0.130 |
Why?
|
| Fibrosis | 1 | 2017 | 169 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 216 | 0.120 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 70 | 0.120 |
Why?
|
| Phenotype | 2 | 2017 | 780 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 1596 | 0.110 |
Why?
|
| NFATC Transcription Factors | 1 | 2015 | 7 | 0.110 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2015 | 18 | 0.110 |
Why?
|
| SOX9 Transcription Factor | 1 | 2015 | 10 | 0.110 |
Why?
|
| RNA Interference | 1 | 2016 | 247 | 0.110 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2014 | 25 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2015 | 38 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 44 | 0.110 |
Why?
|
| Ligands | 1 | 2016 | 388 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 116 | 0.100 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2013 | 16 | 0.100 |
Why?
|
| Apoptosis | 1 | 2020 | 1568 | 0.100 |
Why?
|
| ADAM Proteins | 1 | 2012 | 20 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 1869 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 98 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 694 | 0.090 |
Why?
|
| Phorbol Esters | 1 | 2010 | 8 | 0.080 |
Why?
|
| Leupeptins | 1 | 2010 | 12 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 22 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 127 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 197 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2010 | 109 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 883 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1019 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 986 | 0.060 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 36 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 291 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2017 | 1035 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 652 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2005 | 735 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 495 | 0.040 |
Why?
|
| U937 Cells | 1 | 2019 | 31 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2017 | 18 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 9 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 150 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 411 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 192 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 384 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2015 | 36 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 701 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 173 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 734 | 0.030 |
Why?
|
| Agar | 1 | 2013 | 9 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 36 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 1857 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2013 | 68 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 76 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 383 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 456 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1082 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 434 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 38 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 51 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 98 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 129 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2005 | 150 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2005 | 158 | 0.010 |
Why?
|
| Cadherins | 1 | 2005 | 102 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 368 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 139 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 290 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 532 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 154 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 861 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1604 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1271 | 0.010 |
Why?
|
| Aged | 1 | 2005 | 8214 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 12222 | 0.010 |
Why?
|
| Female | 1 | 2005 | 24698 | 0.000 |
Why?
|